- Home
- ARBK vs BLRX Comparison
ARBK vs BLRX Comparison
Compare ARBK & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ARBK | BLRX |
|---|---|---|
| Founded | 2017 | 2003 |
| Country | United Kingdom | Israel |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.6M | 17.1M |
| IPO Year | 2021 | 2011 |
Fundamental Metrics
Financial Performance| Metric | ARBK | BLRX |
|---|---|---|
| Price | $5.20 | $3.22 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | ★ 96.7K | 28.9K |
| Earning Date | 05-01-2026 | 11-24-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $24,043,000.00 | $12,735,000.00 |
| Revenue This Year | $183.90 | N/A |
| Revenue Next Year | $26.78 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.24 | $2.30 |
| 52 Week High | $205.20 | $14.70 |
Technical Indicators
Market Signals| Indicator | ARBK | BLRX |
|---|---|---|
| Relative Strength Index (RSI) | 76.73 | 45.85 |
| Support Level | $0.12 | $3.14 |
| Resistance Level | $28.64 | $3.43 |
| Average True Range (ATR) | 1.74 | 0.22 |
| MACD | 0.56 | 0.01 |
| Stochastic Oscillator | 17.51 | 22.03 |
Price Performance
Historical ComparisonAbout ARBK Argo Blockchain plc
Argo Blockchain PLC is a blockchain technology company focused on the large-scale mining of Bitcoin. It mines bitcoin using purpose-built computers (or mining machines) to solve complex cryptographic algorithms on the blockchain in exchange for rewards and fees denominated in the native token of that blockchain network. The company acquires and deploys mining technology solutions in North American facilities that utilize predominantly renewable and inexpensive electricity.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.